Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference
Nevro Corp. (NYSE: NVRO) announced the acceptance of data abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) at the NANS 2021 conference, scheduled for January 15, 2021. The PDN trial, the largest randomized controlled trial of spinal cord stimulation (SCS) treatment, will feature 216 subjects and reveal new 12-month pain relief data. The NSRBP study includes 159 participants, presenting its primary endpoint results. Nevro's CEO D. Keith Grossman will hold a virtual investor briefing for updates and Q&A following the presentations.
- The PDN trial is the largest RCT of SCS treatment with 216 subjects.
- Presentation includes promising 12-month pain relief data.
- None
REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced today that both data abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted by the North American Neuromodulation Society (NANS 2021) and will be presented at the conference on January 15, 2021. Each presentation will be ten minutes, followed by a two-minute question and answer session. Following both presentations, Nevro Chairman, CEO and President D. Keith Grossman will host a virtual investor briefing and will provide a business update and answer questions from investors about the Company's latest developments. The timing and details of the briefing will be announced before the January conference.
Painful Diabetic Neuropathy (PDN)
Nevro's PDN trial is the largest randomized controlled trial (RCT) of SCS treatment completed thus far with 216 randomized subjects. The data presented will extend the promising primary endpoint outcomes presented at NANS in January 2020, highlighting complete 6-month results and analysis of all prespecified secondary endpoints. Additionally, a first look at 12-month pain relief will be included. Results will be presented by Dr. Erika A. Petersen, MD from the University of Arkansas for Medical Sciences on January 15, 2021 at NANS 2021 Late-Breaking Abstract Plenary Session 1.
Non-Surgical Refractory Back Pain (NSRBP)
Nevro's NSRBP data presentation will be a first look at primary endpoint results from this RCT investigating spinal cord stimulation efficacy in non-surgical refractive back pain, with 159 randomized participants from 15 study centers. Results will be presented by Dr. Leonardo Kapural, MD, PhD from Wake Forest University, Winston-Salem, NC on January 15, 2021 at NANS 2021 Late-Breaking Abstract Plenary Session 1.
A live webcast of the virtual investor briefing will be available on the Investors section of Nevro's website at www.nevro.com. A webcast replay will be available approximately one hour after the live webcast ends and will be archived on the Company's website.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investor Relations:
Matt Bacso, CFA
The Gilmartin Group
ir@nevro.com
View original content:SOURCE Nevro Corp.
FAQ
What trials will Nevro present at the NANS 2021 conference?
How many subjects are involved in the PDN trial?
When will the investor briefing for Nevro be held?
What are the key outcomes expected from the PDN trial?
What is the focus of Nevro Corp. as a company?
